BACKGROUND AND PURPOSE: Pharmacological analysis of synergism or functional antagonism between different receptors commonly assumes that interacting receptors are located in the same cells. We have now investigated the distribution of alpha-adrenoceptors, beta-adrenoceptors and cannabinoid-like (GPR55) receptors in the mouse arteries. EXPERIMENTAL APPROACH: Fluorescence intensity from vascular tissue incubated with fluorescent ligands (alpha(1)-adrenoceptor ligand, BODIPY-FL-prazosin, QAPB; beta-adrenoceptor ligand, TMR-CGP12177; fluorescent angiotensin II; a novel diarylpyrazole cannabinoid ligand (Tocrifluor 1117, T1117) was measured with confocal microscopy. Small mesenteric and tail arteries of wild-type and alpha(1B/D)-adrenoceptor-KO mice were used. KEY RESULTS: T1117, a fluorescent form of the cannabinoid CB(1) receptor antagonist AM251, was a ligand for GPR55, with low affinity for CB(1) receptors. In mesenteric arterial smooth muscle cells, alpha(1A)-adrenoceptors were predominantly located in different cells from those with beta-adrenoceptors, angiotensin receptors or cannabinoid-like (GPR55) receptors. Cells with beta-adrenoceptors predominated at arterial branches. Endothelial cells expressed beta-adrenoceptors, alpha-adrenoceptors and cannabinoid-like receptors. Only endothelial alpha-adrenoceptors appeared in clusters. Adventitia was a rich source of G protein-coupled receptors (GPCRs), particularly fibroblasts and nerve tracts, where Schwann cells bound alpha-adrenoceptor, beta-adrenoceptor and CB-receptor ligands, with a mix of separate receptor locations and co-localization. CONCLUSIONS AND IMPLICATIONS: Within each cell type, each GPCR had a distinctive heterogeneous distribution with limited co-localization, providing a guide to the possibilities for functional synergism, and suggesting a new paradigm for synergism in which interactions may be either between cells or involve converging intracellular signalling processes.
BACKGROUND AND PURPOSE: Pharmacological analysis of synergism or functional antagonism between different receptors commonly assumes that interacting receptors are located in the same cells. We have now investigated the distribution of alpha-adrenoceptors, beta-adrenoceptors and cannabinoid-like (GPR55) receptors in the mouse arteries. EXPERIMENTAL APPROACH: Fluorescence intensity from vascular tissue incubated with fluorescent ligands (alpha(1)-adrenoceptor ligand, BODIPY-FL-prazosin, QAPB; beta-adrenoceptor ligand, TMR-CGP12177; fluorescent angiotensin II; a novel diarylpyrazole cannabinoid ligand (Tocrifluor 1117, T1117) was measured with confocal microscopy. Small mesenteric and tail arteries of wild-type and alpha(1B/D)-adrenoceptor-KO mice were used. KEY RESULTS: T1117, a fluorescent form of the cannabinoid CB(1) receptor antagonist AM251, was a ligand for GPR55, with low affinity for CB(1) receptors. In mesenteric arterial smooth muscle cells, alpha(1A)-adrenoceptors were predominantly located in different cells from those with beta-adrenoceptors, angiotensin receptors or cannabinoid-like (GPR55) receptors. Cells with beta-adrenoceptors predominated at arterial branches. Endothelial cells expressed beta-adrenoceptors, alpha-adrenoceptors and cannabinoid-like receptors. Only endothelial alpha-adrenoceptors appeared in clusters. Adventitia was a rich source of G protein-coupled receptors (GPCRs), particularly fibroblasts and nerve tracts, where Schwann cells bound alpha-adrenoceptor, beta-adrenoceptor and CB-receptor ligands, with a mix of separate receptor locations and co-localization. CONCLUSIONS AND IMPLICATIONS: Within each cell type, each GPCR had a distinctive heterogeneous distribution with limited co-localization, providing a guide to the possibilities for functional synergism, and suggesting a new paradigm for synergism in which interactions may be either between cells or involve converging intracellular signalling processes.
Authors: Ana M Briones; Craig J Daly; Francesc Jimenez-Altayo; Sonia Martinez-Revelles; Jose M Gonzalez; John C McGrath; Elisabet Vila Journal: Br J Pharmacol Date: 2005-11 Impact factor: 8.739
Authors: Michelle A Uberti; Chris Hague; Heide Oller; Kenneth P Minneman; Randy A Hall Journal: J Pharmacol Exp Ther Date: 2004-12-22 Impact factor: 4.030
Authors: E Ryberg; N Larsson; S Sjögren; S Hjorth; N-O Hermansson; J Leonova; T Elebring; K Nilsson; T Drmota; P J Greasley Journal: Br J Pharmacol Date: 2007-09-17 Impact factor: 8.739
Authors: Markus Waldeck-Weiermair; Cristina Zoratti; Wolfgang F Graier; Karin Osibow; Nariman Balenga; Edith Goessnitzer; Maria Waldhoer; Roland Malli Journal: J Cell Sci Date: 2008-04-29 Impact factor: 5.285
Authors: Claudia Roberta de Andrade; Sandra Yasuyo Fukada; Vania Claudia Olivon; Marcio A F de Godoy; Renato Haddad; Marcos Nogueira Eberlin; Fernando Queiroz Cunha; Heraldo Possolo de Souza; Francisco R M Laurindo; Ana Maria de Oliveira Journal: Eur J Pharmacol Date: 2006-06-10 Impact factor: 4.432
Authors: John D Pediani; Janet F Colston; Darren Caldwell; Graeme Milligan; Craig J Daly; John C McGrath Journal: Mol Pharmacol Date: 2004-12-30 Impact factor: 4.436
Authors: Alexander Emami-Nemini; Thomas Roux; Marion Leblay; Emmanuel Bourrier; Laurent Lamarque; Eric Trinquet; Martin J Lohse Journal: Nat Protoc Date: 2013-06-13 Impact factor: 13.491
Authors: Artur Wnorowski; Justyna Such; Rajib K Paul; Robert P Wersto; Fred E Indig; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer Journal: Cell Signal Date: 2017-05-08 Impact factor: 4.315
Authors: Rajib K Paul; Artur Wnorowski; Isabel Gonzalez-Mariscal; Surendra K Nayak; Karolina Pajak; Ruin Moaddel; Fred E Indig; Michel Bernier; Irving W Wainer Journal: Biochem Pharmacol Date: 2013-12-16 Impact factor: 5.858